AbbVie autoimmune news

AbbVie dropped lawsuits against EMA challenging the agency's decision to grant access to raw patient-level data for autoimmune drug Humira adalimumab. AbbVie filed suit last year in response to a third-party request to EMA for data contained in an MAA for Humira for Crohn's disease. AbbVie withdrew its suits after it and EMA reached an agreement on redactions for the requested data.

Last year, the VP of the European Court of Justice annulled an interim order from the European Union General Court that prevented EMA from releasing data in connection with AbbVie's suits and a separate suit filed by InterMune Inc. (NASDAQ:ITMN, Brisbane, Calif.). ...